Bio-Imaging Technologies Appoints Peter S. Benton President of Its Phoenix Data Systems Division.

NEWTOWN, Pa. -- Bio-Imaging Technologies, Inc. ("Bio-Imaging") (NASDAQ: BITI) today announced that it has appointed Peter S. Benton as President of its Phoenix Data Systems ("PDS") Division. PDS is a leading global clinical data services provider of electronic data capture ("EDC") services offering a comprehensive array of broadly interoperable eClinical data solutions to its pharmaceutical and biotechnology customers. Mr. Benton will succeed Dr. William Claypool, who is leaving PDS to start a pharmaceutical development consulting company, Pennmark Associates, LLC.

Mr. Benton has over twenty years of experience, within and beyond the pharmaceutical research industry, across operations, management, strategic planning and mergers and acquisitions. Most recently, he was chief operating officer of a publicly traded eClinical technology services company, where he was responsible for overall operations including project management, applications development, quality control, customer support and technology integration. Mr. Benton's life sciences experience includes founding and operating his own firm which provided consulting, advisory and investment services to early stage therapeutic, medical device and technology companies. Previously, Mr. Benton was associated with Johnson and Johnson's Pharmaceutical business, where he served as vice president of central planning. Mr. Benton's experience includes general management experience at TRW, Inc.'s automotive sector and General Electric, where he started his career in the manufacturing management program. Mr. Benton holds a BS in Mechanical Engineering from Northeastern University and an MBA from The Wharton School, University of Pennsylvania.

"Peter brings a wealth of general management and strategic corporate development experience to our organization", commented Mark Weinstein, President and CEO of Bio-Imaging. "We are very pleased to welcome Peter to our senior management team and believe that Peter possesses the domain experience and leadership skills necessary to strategically position the company in the rapidly growing eClinical market."

"I am pleased to join PDS, which has an excellent reputation, an outstanding management team and is strategically well positioned with a comprehensive suite of eClinical products and services", stated Peter Benton. "I look forward to continuing the leadership that Dr. Claypool has brought to the company and to working closely with the PDS team to advance the organization during this very important time in its development. The global EDC market is growing rapidly, and I believe PDS has an excellent platform to support significant growth and expansion by helping its pharmaceutical and biotechnology customers streamline the clinical research process and assist its clients in bringing drugs to market faster and more safely."

Bio-Imaging Technologies, Inc. is a healthcare contract service organization providing services that support the product development process of the pharmaceutical, biotechnology and medical device industries. The Company has specialized in assisting its clients in the design and management of the medical imaging component of clinical trials since 1990. Bio-Imaging serves its clients on a global basis through its Core Labs in Newtown, PA, and Leiden, The Netherlands, along with business offices in the United States, The Netherlands, Germany and France. Phoenix Data Systems, Inc., a subsidiary of Bio-Imaging Technologies, is a leading global clinical data services provider of electronic data capture (EDC) services and a comprehensive array of broadly interoperable eClinical data solutions to the pharmaceutical and biotechnology industries. Phoenix Data Systems delivers full service EDC, a unique combination of electronic data capture, interactive voice response, reporting, and data management solutions. Through its CapMed Personal Health Management Suite, Bio-Imaging provides its Personal HealthKey[TM] technology, the Personal Health Record (PHR) software, and CapMed Patient Portal allowing patients to better monitor and manage their health care information. Additional information about Bio-Imaging is available at www.bioimaging.com.

Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the recent form 10-Q.